Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-c...

Full description

Bibliographic Details
Main Authors: Agustín Sancho-Saldaña, Anna Gil Sánchez, Bibiana Quirant-Sánchez, Lara Nogueras, Silvia Peralta, Maria José Solana, Cristina González-Mingot, Yhovanni Gallego, Laura Quibus, Cristina Ramo-Tello, Silvia Presas-Rodríguez, Eva Martínez-Cáceres, Pascual Torres, José Vicente Hervás, Joan Valls, Luis Brieva
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Subjects:
multiple sclerosis
COVID-19
SARS-CoV-2
DMT
seroprevalence
Online Access:https://www.mdpi.com/2077-0383/11/9/2509

Internet

https://www.mdpi.com/2077-0383/11/9/2509

Similar Items